Your browser doesn't support javascript.
loading
CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda, Katarzyna; Buda, Pawel; Matloka, Mikolaj; Mach, Mateusz; Stelmach, Filip; Dzida, Radoslaw; Smuga, Damian; Hucz-Kalitowska, Joanna; Teska-Kaminska, Malgorzata; Vialichka, Varvara; Dubiel, Krzysztof; Kaminska, Bozena; Wieczorek, Maciej; Pieczykolan, Jerzy.
Afiliação
  • Bazydlo-Guzenda K; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.). katarzyna.bazydlo@celonpharma.c
  • Buda P; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Matloka M; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Mach M; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Stelmach F; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Dzida R; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Smuga D; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Hucz-Kalitowska J; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Teska-Kaminska M; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Vialichka V; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Dubiel K; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Kaminska B; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Wieczorek M; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
  • Pieczykolan J; Research and Development Centre, Celon Pharma SA, Kazun Nowy, Poland (K.B.-G., P.B., Mi.M., Ma.M., F.S., R.D., D.S., J.H.-K., M.T.-K., V.V., K.D., M.W., J.P.), and Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland (K.B.-G., B.K.).
Mol Pharmacol ; 100(4): 335-347, 2021 10.
Article em En | MEDLINE | ID: mdl-34349026
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Acoplados a Proteínas G / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Acoplados a Proteínas G / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article